FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status (OPALO)
A Phase II Trial to Evaluate the Efficacy and Safety of FOLFIRI + Panitumumab as First-line Treatment in Elderly Patients With RAS/BRAF Wild-type Unresectable Metastatic Colorectal Cancer and Good Performance Status
Sponsor: Amgen
A PHASE2 clinical study on Colorectal Cancer Metastatic and Colorectal Carcinoma, this trial is completed. The trial is conducted by Amgen and has accumulated 11 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Mar 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE2
-
Sep 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Grupo Espanol Multidisciplinario del Cancer Digestivo
- Pivotal S.L.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Elda, Spain , L'Hospitalet de Llobregat, Spain , Lleida, Spain , Madrid, Spain , Majadahonda, Spain , Murcia, Spain , Móstoles, Spain , Palma, Spain , Sabadell, Spain and 2 more locations